Esperion Therapeutics (ESPR) Short Interest Ratio & Short Volume $2.19 -0.01 (-0.45%) As of 01/3/2025 05:45 PM Eastern Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Esperion Therapeutics Short Interest DataEsperion Therapeutics (ESPR) has a short interest of 25.47 million shares, representing 13.06% of the float (the number of shares available for trading by the public). This marks a -16.46% decrease in short interest from the previous month. The short interest ratio (days to cover) is 4.6, indicating that it would take 4.6 days of the average trading volume of 4.54 million shares to cover all short positions.Current Short Interest25,470,000 sharesPrevious Short Interest30,490,000 sharesChange Vs. Previous Month-16.46%Dollar Volume Sold Short$57.31 millionShort Interest Ratio4.6 Days to CoverLast Record DateDecember 15, 2024Outstanding Shares197,035,000 sharesFloat Size195,080,000 sharesShort Percent of Float13.06%Today's Trading Volume5,678,148 sharesAverage Trading Volume4,541,724 sharesToday's Volume Vs. Average125% Short Selling Esperion Therapeutics? Sign up to receive the latest short interest report for Esperion Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartESPR Short Interest Over TimeESPR Days to Cover Over TimeESPR Percentage of Float Shorted Over Time Esperion Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 12/15/202425,470,000 shares $57.31 million -16.5%13.1%4.6 $2.25 11/30/202430,490,000 shares $85.37 million -2.4%15.6%6.7 $2.80 11/15/202431,250,000 shares $66.25 million -6.6%16.0%8.2 $2.12 10/31/202433,460,000 shares $68.26 million -5.5%17.2%8.8 $2.04 10/15/202435,390,000 shares $75.38 million -5.6%18.2%9.7 $2.13 9/30/202437,470,000 shares $61.83 million -1.6%19.3%9.3 $1.65 Get the Latest News and Ratings for ESPR and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Esperion Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 9/15/202438,090,000 shares $72.75 million -5.8%19.6%6.9 $1.91 8/31/202440,440,000 shares $74.01 million -3.1%20.8%6.4 $1.83 8/15/202441,730,000 shares $82.21 million +9.4%21.5%6 $1.97 7/31/202438,140,000 shares $88.10 million -3.3%22.2%5.1 $2.31 7/15/202439,420,000 shares $98.55 million +67.4%25.5%4.8 $2.50 6/30/202423,550,000 shares $52.28 million -5.4%15.2%2.8 $2.22 6/15/202424,890,000 shares $74.42 million +13.7%16.1%3 $2.99 5/31/202421,890,000 shares $47.28 million -12.1%14.2%2.8 $2.16 5/15/202424,910,000 shares $57.29 million +25.4%16.1%3.4 $2.30 4/30/202419,870,000 shares $39.14 million +6.8%11.8%2.9 $1.97 4/15/202418,600,000 shares $35.99 million -6.6%11.0%3 $1.94 3/31/202419,920,000 shares $53.39 million +12.7%11.8%3 $2.68 3/15/202417,670,000 shares $36.58 million +4.3%10.5%2.8 $2.07 2/29/202416,950,000 shares $42.54 million -8.7%10.0%2.8 $2.51 2/15/202418,570,000 shares $49.40 million -7.5%11.0%3 $2.66 1/31/202420,070,000 shares $42.95 million -0.6%11.9%3.3 $2.14 1/15/202420,200,000 shares $61.00 million +1.4%17.9%3.7 $3.02 12/31/202319,920,000 shares $59.56 million +9.2%17.7%4.3 $2.99 12/15/202318,240,000 shares $33.20 million +2.8%16.2%4.3 $1.82 11/30/202317,740,000 shares $23.59 million -3.1%15.7%4.6 $1.33 11/15/202318,310,000 shares $21.06 million +0.5%16.2%4.7 $1.15 10/31/202318,220,000 shares $15.10 million -5.2%17.2%4.8 $0.83 10/15/202319,220,000 shares $15.95 million -3.0%18.1%5 $0.83 9/30/202319,810,000 shares $19.41 million +20.4%18.7%5.5 $0.98 9/15/202316,460,000 shares $23.37 million +8.4%15.5%4.7 $1.42 8/31/202315,180,000 shares $24.29 million +8.5%14.3%4.8 $1.60 8/15/202313,990,000 shares $22.94 million +4.3%13.2%5 $1.64 7/31/202313,410,000 shares $21.05 million +2.9%12.7%4.9 $1.57 7/15/202313,030,000 shares $18.76 million +4.2%13.9%5.4 $1.44 6/30/202312,510,000 shares $17.39 million -9.9%13.3%5.1 $1.39 6/15/202313,880,000 shares $19.02 million +3.8%14.8%5 $1.37 5/31/202313,370,000 shares $18.18 million -8.4%14.3%3.6 $1.36 5/15/202314,600,000 shares $24.82 million No Change15.6%3.5 $1.70 10/31/202214,030,000 shares $114.06 million +5.3%N/A11.6 $8.13 10/15/202213,330,000 shares $101.31 million +6.6%N/A11.5 $7.60 9/30/202212,500,000 shares $83.75 million -0.9%N/A12.1 $6.70 9/15/202212,610,000 shares $94.83 million -5.5%N/A12.6 $7.52 8/31/202213,350,000 shares $99.59 million +8.6%N/A13.9 $7.46 8/15/202212,290,000 shares $81.97 million -1.8%N/A13.7 $6.67 7/31/202212,520,000 shares $72.24 million +3.2%N/A12.9 $5.77 7/15/202212,130,000 shares $81.39 million +2.6%N/A11.8 $6.71 6/30/202211,820,000 shares $75.18 million +6.8%N/A10.2 $6.36 6/15/202211,070,000 shares $59.00 million -4.2%N/A9.1 $5.33 5/31/202211,560,000 shares $65.89 million +13.7%N/A8.7 $5.70 5/15/202210,170,000 shares $58.78 million +15.8%N/A7.3 $5.78 4/30/20228,780,000 shares $49.87 million +10.0%N/A6.4 $5.68 4/15/20227,980,000 shares $47.00 million +8.7%N/A6.3 $5.89 3/31/20227,340,000 shares $34.06 million +36.7%N/A0 $4.64 3/15/20225,370,000 shares $24.70 million +29.7%N/A4 $4.60 2/28/20224,140,000 shares $16.93 million +18.0%N/A2.7 $4.09 2/15/20223,510,000 shares $14.00 million +11.4%N/A1.6 $3.99 1/31/20223,150,000 shares $13.51 million -3.7%N/A1.4 $4.29 1/15/20223,270,000 shares $12.85 million -62.2%N/A1.5 $3.93 12/31/20218,650,000 shares $43.25 million +10.6%N/A3.9 $5.00 12/15/20217,820,000 shares $41.84 million -20.9%N/A3.8 $5.35 11/30/20219,880,000 shares $86.25 million +11.5%N/A5.2 $8.73 11/15/20218,860,000 shares $77.26 million -3.5%N/A8.1 $8.72 10/29/20219,180,000 shares $82.07 million +15.2%N/A9.5 $8.94 10/15/20217,970,000 shares $72.85 million +8.7%28.7%9.3 $9.14 9/30/20217,330,000 shares $88.33 million -10.0%26.4%9.7 $12.05 9/15/20218,140,000 shares $92.31 million +0.5%29.3%11.4 $11.34 8/31/20218,100,000 shares $105.46 million -7.1%29.2%14.1 $13.02 8/13/20218,720,000 shares $121.30 million -3.3%31.4%15.4 $13.91 7/30/20219,020,000 shares $138.82 million -5.1%32.5%14.5 $15.39 7/15/20219,500,000 shares $167.96 million +5.2%34.3%14.1 $17.68 6/30/20219,030,000 shares $190.98 million +0.9%32.6%13.7 $21.15 6/15/20218,950,000 shares $221.96 million -0.4%32.3%14.2 $24.80 5/28/20218,990,000 shares $178.99 million -1.5%32.4%13.8 $19.91 5/14/20219,130,000 shares $204.51 million -5.8%N/A13.4 $22.40 4/30/20219,690,000 shares $264.63 million -0.8%40.8%14.1 $27.31 4/15/20219,770,000 shares $265.26 million +3.3%N/A14 $27.15 3/31/20219,460,000 shares $259.58 million -3.1%N/A12.1 $27.44 3/15/20219,760,000 shares $296.12 million -3.5%N/A11.7 $30.34 2/26/202110,110,000 shares $279.84 million +5.9%N/A12.2 $27.68 2/12/20219,550,000 shares $293.57 million -5.8%35.5%11.7 $30.74 1/29/202110,140,000 shares $325.70 million -8.5%37.7%12.3 $32.12 1/15/202111,080,000 shares $296.39 million +2.8%N/A12.9 $26.75 12/31/202010,780,000 shares $303.46 million +6.5%N/A15.7 $28.15 12/15/202010,120,000 shares $299.35 million +3.5%44.0%15.5 $29.58 11/30/20209,780,000 shares $264.26 million +0.9%42.5%16 $27.02 11/15/20209,690,000 shares $278.01 million -3.7%42.1%15.2 $28.69 10/30/202010,060,000 shares $315.48 million -0.7%43.7%16.3 $31.36 10/15/202010,130,000 shares $342.19 million -9.1%N/A17.5 $33.78 9/30/202011,140,000 shares $414.07 million -0.3%N/A18.6 $37.17 9/15/202011,170,000 shares $414.74 million -3.5%N/A18 $37.13 8/31/202011,570,000 shares $417.68 million +5.1%N/A17.6 $36.10 8/14/202011,010,000 shares $361.24 million +1.2%40.9%16.2 $32.81 7/31/202010,880,000 shares $409.41 million +3.8%40.7%15.8 $37.63 7/15/202010,480,000 shares $496.96 million +3.5%39.2%16.3 $47.42 6/30/202010,130,000 shares $482.59 million +8.1%37.9%15.4 $47.64 6/15/20209,370,000 shares $411.81 million +15.4%35.1%13.6 $43.95 5/29/20208,120,000 shares $332.43 million -2.8%30.4%10.4 $40.94 5/15/20208,350,000 shares $372.58 million +7.6%31.2%9.9 $44.62 4/30/20207,760,000 shares $307.30 million +2.0%29.0%8.2 $39.60 4/15/20207,610,000 shares $261.94 million +8.6%28.5%8.2 $34.42 3/31/20207,010,000 shares $281.31 million +12.9%26.9%7.8 $40.13 3/13/20206,209,100 shares $220.80 million -9.4%23.8%7.2 $35.56 2/28/20206,850,000 shares $244.89 million +30.2%26.3%9.6 $35.75 2/14/20205,260,000 shares $246.06 million +7.6%20.3%7.9 $46.78 1/31/20204,890,000 shares $278.97 million +1.2%19.3%9.4 $57.05 1/15/20204,830,000 shares $319.75 million -2.6%19.1%10.2 $66.20 ESPR Short Interest - Frequently Asked Questions What is Esperion Therapeutics' current short interest? Short interest is the volume of Esperion Therapeutics shares that have been sold short but have not yet been closed out or covered. As of December 15th, investors have sold 25,470,000 shares of ESPR short. 13.06% of Esperion Therapeutics' shares are currently sold short. Learn More on Esperion Therapeutics' current short interest. What is a good short interest ratio for Esperion Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. ESPR shares currently have a short interest ratio of 5.0. Learn More on Esperion Therapeutics's short interest ratio. Which institutional investors are shorting Esperion Therapeutics? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Esperion Therapeutics: Wolverine Trading LLC, Point72 Asset Management L.P., and Bank of Montreal Can. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. What is a good short interest percentage for Esperion Therapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 13.06% of Esperion Therapeutics' floating shares are currently sold short. Is Esperion Therapeutics' short interest increasing or decreasing? Esperion Therapeutics saw a drop in short interest during the month of December. As of December 15th, there was short interest totaling 25,470,000 shares, a drop of 16.5% from the previous total of 30,490,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Esperion Therapeutics' float size? Esperion Therapeutics currently has issued a total of 197,035,000 shares. Some of Esperion Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Esperion Therapeutics currently has a public float of 195,080,000 shares. How does Esperion Therapeutics' short interest compare to its competitors? 13.06% of Esperion Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Esperion Therapeutics: Xencor, Inc. (5.87%), Arcutis Biotherapeutics, Inc. (19.74%), Evotec SE (0.15%), Immunocore Holdings plc (14.51%), Praxis Precision Medicines, Inc. (8.84%), Kiniksa Pharmaceuticals, Ltd. (4.52%), Arcus Biosciences, Inc. (15.00%), Travere Therapeutics, Inc. (9.49%), Nurix Therapeutics, Inc. (13.88%), Ocular Therapeutix, Inc. (6.66%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: AppLovin Co. ($5.70 billion), Charter Communications, Inc. ($4.32 billion), Spotify Technology S.A. ($4.06 billion), Canadian Natural Resources Limited ($3.45 billion), Reddit, Inc. ($2.79 billion), International Paper ($2.70 billion), Cencora, Inc. ($2.27 billion), SoFi Technologies, Inc. ($2.21 billion), Lululemon Athletica Inc. ($2.13 billion), and Rivian Automotive, Inc. ($2.05 billion). View all of the most shorted stocks. What does it mean to sell short Esperion Therapeutics stock? Short selling ESPR is an investing strategy that aims to generate trading profit from Esperion Therapeutics as its price is falling. ESPR shares are trading down $0.01 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Esperion Therapeutics? A short squeeze for Esperion Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of ESPR, which in turn drives the price of the stock up even further. How often is Esperion Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including ESPR, twice per month. The most recent reporting period available is December, 15 2024. More Short Interest Resources from MarketBeat Related Companies Xencor Short Squeeze Arcutis Biotherapeutics Short Squeeze Evotec Short Squeeze Immunocore Short Squeeze Praxis Precision Medicines Short Squeeze Kiniksa Pharmaceuticals Short Squeeze Arcus Biosciences Short Squeeze Travere Therapeutics Short Squeeze Nurix Therapeutics Short Squeeze Ocular Therapeutix Short Squeeze Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:ESPR) was last updated on 1/5/2025 by MarketBeat.com Staff From Our Partners Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | Sponsoredliberals FOOLED by Elon’s shocking surpriseElon Musk and Donald Trump fooled everyone. They said it was to “save free speech”... Or “fix what the l...StocksToTrade | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredDeFi Coin on Verge of Breakout!The blueprint for millionaires is here. Don't let this be the missed opportunity you regret for years. Crypto 101 Media | SponsoredStunning Trump Exec Order LeakedMost people have no clue this unassuming facility exists. Yet the minute Donald Trump takes office... ...Banyan Hill Publishing | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredI was wrong. Dead wrong. Something is stirring deep in Silicon Valley. My team and I have been watching the tech markets closely. ...Porter & Company | SponsoredAmazon coin set to soar 25X – starting January 20thThis tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Esperion Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Esperion Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.